GSK (LON: GSK) delivered a robust first quarter for 2026, driven by double-digit growth in its Specialty Medicines portfolio. Despite management reiterating full-year guidance and showcasing strong pipeline momentum, markets reacted cautiously, sending shares down 1.9% in the wake of the print.
Revenue: Total Q1 sales reached £7.6 billion, representing a 5% increase at constant exchange rates (CER). At this growth rate, the top line is tracking comfortably within the firm’s projected 3% to 5% full-year target, despite adverse sterling movements against the dollar.
Profit & Margins: Core operating profit grew 10% CER to £2.65 billion, translating to a core operating margin expansion of 1.8 percentage points to 34.7%. This profitability beat was fuelled by a favourable regional product mix, higher royalty income, and disciplined SG&A spending.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Cash & Balance Sheet: Cash generated from operations stood at a healthy £1.4 billion, yielding £800 million in free cash flow. This gives the pharmaceutical giant ample balance sheet flexibility to continue R&D investments and pursue bolt-on pipeline acquisitions.
Management remains highly committed to returning capital, declaring a Q1 dividend of 17p per share with a clear path toward a 70p full-year payout. Furthermore, the company has already executed £1.7 billion of its £2 billion share buyback programme initiated last year.
Driver Breakdown Box
- Specialty Medicines Surge: The segment jumped 14% to £3.2 billion, heavily lifted by Oncology sales (+28%) and Respiratory, Immunology & Inflammation (+16%).
- Vaccine Resilience: Vaccines posted a 4% gain to £2.1 billion, anchored by a massive £1.0 billion contribution from Shingrix (+20%), which successfully offset a steep 18% decline in Arexvy.
- Tariff Relief: A definitive agreement with the US Government shields GSK and ViiV Healthcare from Section 232 tariffs through January 2029, removing a significant overhang on future gross margins.
AskTraders Takeaway: So what does this mean for the stock? The 1.9% dip in shares likely reflects broader macroeconomic positioning and minor market concerns over the 6% contraction in General Medicines, rather than a fundamental flaw in the Q1 print. The reaffirmed guidance highlights underlying operational stability, making the post-earnings pullback a potential area of interest for value-oriented participants.
Watch the R&D pipeline progression into the second half of the year. With regulatory filings accepted for bepirovirsen—a potential functional cure for chronic hepatitis B—and updated Phase III plans for oncology ADCs, clinical execution could serve as a major upside catalyst.
CEO Luke Miels stated, “GSK has made a strong start to 2026, with good performance from our key growth drivers,” reinforcing the company’s focus on execution and accelerating R&D through strategic acquisitions like ozureprubart for food allergies.
Analyst Summary: Bull and Bear Cases
Bull Case:
- Specialty Medicines surged 14%, driven by strong Oncology (+28%) and Respiratory/Immunology (+16%) sales.
- Core operating profit grew 10% CER, expanding margins by 1.8 percentage points to 34.7%.
- Robust free cash flow of £800 million supports shareholder returns, including a 17p dividend and ongoing share buybacks.
- Definitive agreement provides critical relief from Section 232 tariffs through January 2029.
Bear Case:
- General Medicines experienced a 6% contraction, sparking minor market concerns.
- Arexvy sales saw a steep 18% decline during the quarter.
- Adverse sterling movements against the dollar continue to impact top-line optics.
- Despite a solid earnings print, cautious market positioning pushed the stock 1.9% lower.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
